Taysha Gene Therapies, Inc. · NASDAQ:TSHA
Nagendran Sukumar sold 200,000 Taysha Gene Therapies, Inc. shares (Form 4)
Traded Apr 10, 2026 · Filed Apr 13, 2026
On Apr 10, 2026, Nagendran Sukumar (Director, President and Head of R&D) sold 200,000 Taysha Gene Therapies, Inc. shares at US$4.46 for US$892K under a trading plan, leaving 1,136,410 shares. Filed Apr 13, 2026 (Form 4).
- Sold
- 200,000 shares
- Price
- US$4.46
- Value
- US$892K
- Holding after
- 1,136,410 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, President and Head of R&D
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 10, 2026 | Common Stock | Option exercise | 19,021 | US$1.71 | 1,336,410 | Direct |
| Apr 10, 2026 | Common Stock | Sale | 200,000 | US$4.46 | 1,136,410 | Direct |
Source
Related
- Taysha Gene Therapies, Inc.
- Nagendran Sukumar
- Taysha Gene Therapies, Inc. shareholders
- Form 4 · Nagendran Sukumar · Jul 10, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Aug 14, 2026
- Schedule 13G/A · Morgan Stanley · Aug 13, 2026
- Form 4 · Stalfort John A III · Jun 2, 2026
- Form 4 · Donenberg Phillip B. · Jun 2, 2026
- Form 4 · Long Alison S · Jun 2, 2026